Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Tapentadol ER TRF vs PR2 in Healthy Subjects
NCT02019485Phase 1Completed
- Sponsor
- Johnson & Johnson
- Start
- Jul 2010
- Primary completion
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tapentadol in pain (2 arms), sponsored by Johnson & Johnson. Primary endpoints: Maximum serum concentration of tapentadol, Time to reach maximum serum concentration and 4 more. Started Jul 2010; status: completed.
02
Drugs
tapentadol
03
Conditions
pain
Beyond the preview
Go deeper on NCT02019485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02019485.